Arthritis drug could help treat advanced skin cancer

December 19, 2017, University of East Anglia
Arthritis drug could help treat advanced skin cancer
Credit: University of East Anglia

Treatment for the most deadly form of skin cancer could be more effective if combined with a well-known drug for rheumatoid arthritis, new research has shown.

The study, by scientists at the University of East Anglia (UEA), found that in mice, using the two treatments together almost completely stopped the growth of a tumour.

Although only five per cent of cases involve melanoma, it causes the majority of deaths from the disease. If caught early, melanoma is very treatable, but once the cancer has metastasised or spread, then treatment becomes more difficult.

In recent years, a number of new treatments have been developed for , some targeting certain genetic mutations. However, the disease can quickly become resistant to most drugs, so research is focusing on combinations of treatments, as lead researcher, Dr. Grant Wheeler from UEA's School of Biological Sciences, explains.

"By combining therapies, it's possible to attack the disease from several angles, which makes it harder for the melanoma to develop resistance to any of the drugs," he said.

"Our research has shown that there could also be further benefits – by joining these two drugs together you may be able to enhance their effects, getting a treatment that is more than the sum of its parts."

Dr. Wheeler, working with colleagues from Norwich Medical School and UEA's School of Pharmacy, focused on , an immunosuppressive drug approved for treatment of . Previous research by the team had shown it to be effective in use with drugs that target melanoma with a certain genetic mutation, known as BRAFV600E. Their latest research – published in the journal Oncotarget – has discovered more about how leflunomide works against melanoma and tested it in combination with another melanoma drug, selumetinib.

Selumetinib is one of a number of drugs that target the activity of a protein called MEK, to which melanoma is addicted for its survival. MEK inhibitors are already used in combination with BRAF inhibitors to combat resistance, but Dr. Wheeler's research – part-funded by the John Jarrold Trust – shows that adding leflunomide to the mix may make it even more effective.

When the team tested leflunomide in the lab, it was found to work on melanoma cells irrespective of the genetic signature of the cancer. This means that leflunomide has the potential to be used in all melanoma cases, not just for tumours harbouring BRAF mutations.

The team looked specifically at how leflunomide was acting on the melanoma cells and found that it was able to stop the cells in an early phase of their growth and then force them to kill themselves, a process known as apoptosis.

But when the scientists tested leflunomide on jointly with selumetinib, they found it was more effective than either drug on its own. This finding was replicated in tests on mice with melanoma tumours: using the two drugs together almost completely halted the growth of the tumour over a 12 day period, which far outstripped the effect of either drug used in isolation.

However, many questions remain to be answered before this combination could go into clinical trials, including testing whether melanoma can develop resistance to the .

Dr. Wheeler said: "With melanoma treatments, the main problem has been the development of tumour resistance. One way this is being combatted is through immunotherapy treatments which harness the body's own defences. However, new combination therapies are always needed and we need to identify new drugs that can be added to the arsenal of anti-melanoma therapies available for patients. It's possible that leflunomide could play that role."

"The anti-rheumatic , leflunomide, synergizes with MEK inhibition to suppress melanoma growth" is published in the journal Oncotarget on December 19, 2017.

Explore further: Role of melanoma-promoting protein revealed

More information: The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth. Oncotarget. DOI: 10.18632/oncotarget.23378

Related Stories

Role of melanoma-promoting protein revealed

December 6, 2017
In a new study, Yale researchers describe the role of a protein that promotes growth of melanoma, the deadliest form of skin cancer.

New insight into drug resistance in metastatic melanoma

June 3, 2014
(Medical Xpress)—A study by scientists in Manchester has shown how melanoma drugs can cause the cancer to progress once a patient has stopped responding to treatment.

Scientists identify novel therapeutic targets for metastatic melanoma

November 27, 2017
Mount Sinai researchers have identified novel therapeutic targets for metastatic melanoma, according to a study published in Molecular Cell.

Researchers discover mechanism leading to BRAF inhibitor resistance in melanoma

June 19, 2015
The development of targeted therapies has significantly improved the survival of melanoma patients over the last decade; however, patients often relapse because many therapies do not kill all of the tumor cells, and the remaining ...

Melanoma's 'safe haven' targeted for shut-down

April 13, 2015
Melanoma cells become drug resistant by using surrounding healthy cells to provide a 'safe haven' from treatment, according to new research published in Cancer Cell today.

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.